Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
| Autor: | J.C. van Denderen, Mike J L Peters, Gertjan Wolbink, L. A. Aarden, Ben A. C. Dijkmans, M.K. de Vries, Michael T. Nurmohamed, S.O. Stapel, I E van der Horst-Bruinsma |
|---|---|
| Přispěvatelé: | AII - Amsterdam institute for Infection and Immunity, General Internal Medicine, Landsteiner Laboratory, Faculteit der Geneeskunde, Rheumatology, Internal medicine, Pathology, CCA - Innovative therapy, ICaR - Ischemia and repair |
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Immunology Gastroenterology Antibodies Receptors Tumor Necrosis Factor General Biochemistry Genetics and Molecular Biology Etanercept Antigen-Antibody Reactions Rheumatology immune system diseases Internal medicine Humans Immunology and Allergy Medicine Spondylitis Ankylosing Prospective Studies skin and connective tissue diseases BASDAI Ankylosing spondylitis business.industry Immunogenicity Middle Aged medicine.disease Connective tissue disease stomatognathic diseases Logistic Models Treatment Outcome Antirheumatic Agents Immunoglobulin G Rheumatoid arthritis Female Tumor necrosis factor alpha business Follow-Up Studies medicine.drug |
| Zdroj: | Annals of the rheumatic diseases, 68(4), 531-535. BMJ Publishing Group de Vries, M K, van der Horst-Bruinsma, I E, Nurmohamed, M T, Aarden, L, Stapel, S N, Peters, M J L, van Denderen, A C, Dijkmans, B A C & Wolbink, G 2009, ' Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis ', Annals of the Rheumatic Diseases, vol. 68, no. 4, pp. 531-535 . https://doi.org/10.1136/ard.2008.089979 Annals of the Rheumatic Diseases, 68(4), 531-535. BMJ Publishing Group |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/ard.2008.089979 |
| Popis: | Background:Immunogenicity, specifically the onset of antibodies against tumour necrosis factor (TNF) blocking agents, seems to play an important role in non-response to treatment with these drugs.Objectives:To assess the relation of clinical response of ankylosing spondylitis (AS) to etanercept with etanercept levels, and the presence of antibodies to etanercept.Methods:Patients with AS were treated with etanercept 25 mg twice weekly, according to the international Assessment in Ankylosing Spondylitis (ASAS) working group consensus statement. Sera were collected at baseline and after 3 and 6 months of treatment. Clinical response was defined as a 50% improvement or as an absolute improvement of 2 points on a (0–10 scale) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score. Functional etanercept levels were measured by a newly developed ELISA, measuring the binding of etanercept to TNF. Antibodies against etanercept were measured with a two-site assay and antigen binding test. Clinical data were used to correlate disease activity with serum etanercept levels.Results:In all, 53 consecutive patients were included. After 3 months of treatment 40 patients (76%) fulfilled the response criteria. Mean etanercept levels were 2.7 mg/litre and 3.0 mg/litre after 3 and 6 months respectively. Characteristics and etanercept levels of responders and non-responders were similar. No antibodies to etanercept were detected with any of the assays.Conclusion:Etanercept levels of responders and non-responders were similar and no antibodies to etanercept were detected with any of the assays. This study indicates that etanercept is much less immunogenic compared with the other TNF-blocking agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|